Wird geladen...
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of intravitreal ranibizumab therapy for neovascula...
Gespeichert in:
| Veröffentlicht in: | Int J Retina Vitreous |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5304393/ https://ncbi.nlm.nih.gov/pubmed/28289548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40942-016-0058-3 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|